Vir Biotechnology, Inc. (VIR)

NMS – Цена в реальном времени. Валюта: USD

9.40

+0.11 (1.18%)

При закрытии: May 12, 2026, 4:00 PM EDT

9.47

+0.07 (0.74%)

После закрытия: May 12, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Vir Biotechnology, Inc. (VIR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Search stocks

Vir Biotechnology, Inc. (VIR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer